Last €39.24 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 12:57 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BRM) Snapshot

Open
€39.65
Previous Close
€39.24
Day High
€39.70
Day Low
€39.24
52 Week High
01/13/14 - €41.71
52 Week Low
06/10/14 - €34.12
Market Cap
65.1B
Average Volume 10 Days
840.2
EPS TTM
--
Shares Outstanding
1.7B
EX-Date
10/1/14
P/E TM
--
Dividend
€1.46
Dividend Yield
2.73%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BRM)

bristol-myers squibb co (BRM) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company’s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances and collaborations with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

28,000 Employees
Last Reported Date: 02/14/14
Founded in 1887

bristol-myers squibb co (BRM) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $1.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $901.1K
Chief Operating Officer and Director
Total Annual Compensation: $748.3K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $736.1K
General Counsel and Corporate Secretary
Total Annual Compensation: $843.1K
Compensation as of Fiscal Year 2013.

bristol-myers squibb co (BRM) Key Developments

Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO(R) (nivolumab) and IMBRUVICA(R) (ibrutinib) in Non-Hodgkin Lymphoma

Bristol-Myers Squibb Company, Pharmacyclics Inc. and Janssen Research & Development, LLC announced they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor OPDIVO(R) (nivolumab) in combination with IMBRUVICA(R) (ibrutinib), an oral Bruton's tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Bristol-Myers Squibb has proposed the name OPDIVO (pronounced op-dee-voh), which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body's own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies.

Bristol-Myers Squibb Company Presents at BioFlorida Annual Conference, Oct-13-2014 08:50 AM

Bristol-Myers Squibb Company Presents at BioFlorida Annual Conference, Oct-13-2014 08:50 AM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Lee Evans, Executive Director and Site Leader, North America Center.

Bristol-Myers Squibb Company and MD Anderson Cancer Center of the University of Texas Announce Immuno-Oncology Partnership

Bristol-Myers Squibb and the MD Anderson Cancer Centre of the University of Texas have announced their immuno-oncology collaboration that will focus on advancement of novel therapies for the treatment of acute or chronic leukaemia and other haematologic malignancies. The clinical research partnership will include programmed cell death protein 1 (PD-1) inhibitor Opdivo (nivolumab) and CTLA-4 inhibitor Yervoy (ipilimumab), as well as three undisclosed early-stage immuno-oncology candidates in BMS's pipeline. Up to 10 Phase I and Phase II clinical trials will be launched and conducted by the centre, investigating several monotherapy and combination regimens to treat acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, myelodysplastic syndrome, and myelofibrosis. The two partners will determine if additional clinical trials will be launched at a later time.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRM:GR €39.24 EUR 0.00

BRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $54.41 USD 0.00
Amgen Inc $137.51 USD 0.00
AstraZeneca PLC 4,170 GBp -17.00
Biogen Idec Inc $311.41 USD +4.70
Novo Nordisk A/S kr260.80 DKK +2.60
View Industry Companies
 

Industry Analysis

BRM

Industry Average

Valuation BRM Industry Range
Price/Earnings 31.3x
Price/Sales 5.2x
Price/Book 5.5x
Price/Cash Flow 31.1x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.